SensoDetect

"We're revolutionizing neurodiagnostics," declares PA Hedin, CEO of SensoDetect AB. "Our breakthrough SensoDetect Diagnostics (SDD) system will transform the current 6-18-month diagnostic process into a 30-minute clinical procedure, including world-first newborn screening capabilities. In a market serving 78 million undiagnosed cases, we're uniquely positioned to drive both clinical impact and strong returns."

Market Opportunity 

- €6.8B global ASD/ADHD diagnostics market 

- 1 in 36 children affected by ASD (CDC 2023) 

- Critical need for early intervention (before age 3) 

Proven Solution 

Objective ABR+AI analysis 

Mass screening capability 

Already deployed in Middle East clinics 

Revenue Drivers 

- Hardware: €2K-€50K/unit 

- Testing: €300/assessment (80% margins) 

- Telemedicine: €200/month subscriptions 

Growth Catalysts 

- 2025: Saudi commercialization 

- 2025: China NMPA approval

- 2026: China commercialization

- 2027: US expansion 

"What sets us apart," continues CEO Hedin, "is our ability to turn this healthcare crisis into a €6.8 Billion market opportunity while delivering life-changing screening and diagnostics. We're not just participating in the neurodiagnostic space - we're redefining it," emphasizes CEO Hedin. "With secured regulatory approvals and clear regulatory pathways, we're targeting 10% market share by 2030." 

Data verified via [CDC](https://www.cdc.gov) | [SEC](https://www.sec.gov) | [SFDA](https://www.sfda.gov.sa)